PATENT CLAIM ANALYSIS

Application Number: 16061974
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["514", "314000"]

Abstract:
The present invention relates to methods of treating patients with advanced forms of cancer, such as clear cell renal cell carcinoma, in which X4P-001 is administered in order to reduce angiogenic escape that typically occurs with TKI therapy. The methods demonstrate surprising results, including regression of tumor size and cell number, with comparatively little toxicity.

Claim (Index 5):
The composition according to any one of  claims 1 - 4 , wherein the X4P-001, or a pharmaceutically acceptable salt thereof, is present in an amount of about 10 mg, about 20 mg, about 25 mg, about 50 mg, about 75 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 400 mg, about 450 mg, about 500 mg, about 600 mg, about 700 mg, about 750 mg, about 800 mg, about 900 mg, about 1000 mg, about 1100 mg, or about 1200 mg.

Metadata:
- Claim Count in Document: 49.0
- Percentile: 94.0
- Lexical Diversity: 1.29787
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12937630', '15553570', '15805390', '14905776', '12671287']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7351171098463164
- 35 USC 102 Novelty (BERT): 0.5068137586123843
- Combined Prediction Score: 0.7122867747229232
- Mean Citation Score: 186.025422
- Max Citation Score: 194.66278
- Similarity Product: 126.79253845330716

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test